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（17-OHCS）2） was considered an indicator of stress ─
i.e. a stress marker ─ although the diagnosis of stress 
had until then been based on the results of interviews 
or psychological tests. Urinary 17-OHCS/creatinine in 
patients with advanced cancer, severe diabetes melli-
tus, myocardial infarction, hypertension and obesity, al-
cohol abuse, or psychosocial stress 3） was higher than 
in age-matched controls. However, there is no report 
concerned with urinary 17-OHCS/creatinine in chil-
dren with pervasive developmental disorder （PDD）. 
Currently, the diagnosis of PDD is based on parent in-
terviews, questionnaires, and direct observations in ac-
cordance with the criteria in the Diagnostic and Statis-
tical Manual of Mental Disorders, 4th edition. To our 
????????????
Selye H1） defined the three major clinicopathologcial 
signs of stress as atrophy of the lymph tissues, gastro-
intestinal bleeding, and aggravation of function in the 
adrenal cortex. Stress was considered to be the rate of 
wear and tear, and urinary 17-hydroxycorticosteroid 
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The purpose of this study is to examine urinary 17-hydroxycorticosteroid （OHCS） excretion as a mea-
sure of stress response in controls and in children with pervasive developmental disorders （PDDs） accom-
panied by mental retardation （MR, intelligence quotient ［IQ］＜70） （low-functioning PDD：LFPDD） or not 
accompanied by MR （IQ≧70） （high-functioning PDD：HFPDD）. Prospective, non-randomized study of 24 
children with LFPDD ─ 17 with autism and seven with PDDs not otherwise specified （PDDs-NOS） ─ and 
14 children with HFPDD ─ 11 with PDDs-NOS and three with Asperger’s disorders. Urinary 17-OHCS 
was measured between June 2002 and June 2004. In 21 of 24 LFPDD subjects and 8 of 14 HFPDD subjects 
a second measurement was taken 6 to 12-months after the first, after the subjects had received interven-
tion for developmental disorders. Baseline urinary 17-OHCS levels in both LFPDD （p＜0.0005） and HFPDD 
（p＜0.005） were significantly higher than in controls. LFPDD subjects had significantly greater （p＜0.05） 
levels of this stress hormone than did HFPDD subjects. Levels of 17-OHCS in both LFPDD （p＜0.05） and 
HFPDD （p＜0.05） decreased significantly after 6 to 12 months of intervention. PDD subjects showed higher 
levels of 17-OHCS than controls and showed a significant reduction in the level of stress indicator after they 
had received intervention for developmental disorders.
???? ????： pervasive developmental disorders, mental retardation, stress, 17-hydroxycorticosteroids, 
children
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with a mean age of 7 .8years （SD＝2.1）. The control 
group was recruited from the renal clinic of our hospi-
tal. All control children were in a chronic state, and 
their urine examination did not reveal any abnormali-
ties. The urine data were not influenced by collection 
season or day of the week. Urinary 17-OHCS levels in 
the controls were unchanged before and after staying 
out overnight. In typically developed children, the 17-
OHCS/creatinine showed no difference by age5）.
All children lived at home and traveled to their plac-
es of intervention, and to their community preschools 
or primary schools. They had a regular consultation 
for developmental delay at a child guidance clinic or 
public health center once a month and a public health 
nurse visited home or community preschool or prima-
ry school for an interview. Some children went to spe-
cial classes or schools for mentally or physically handi-
capped children.
Twenty of the 24 LFPDD subjects and 8 of the 14 
HFPDD subjects had chief complaints of speech delay 
or communication disorder. The most notable behav-
ioral peculiarities in our subjects were compulsions to 
line things up exactly or watch revolving objects such 
as fans in ventilators. Subjects tended to draw two-di-
mensional pictures, a picture of a catalog, a picture of 
poor body image, or an accurate picture.
In our hospital, the main therapy for PDD subjects 
in the first 6 months was modification of the living en-
vironment, including regulation of the circadian 
rhythm. Circadian rhythm was irregular in 12 of 24 
LFPDD subjects and three of 14 HFPDD subjects at 
the time of the first medical examination. We defined 
irregular circadian rhythm as being awake past 10 
p.m. or asleep past 8 a.m.. We recommended going to 
bed early and getting up early. We used a sleep-wake-
fulness cycle diary to check the bedtime and the time 
of rising in the morning. We also recommended that 
subjects not spend large periods of time watching 
TV；we aimed for less than 2 hours a day. We also 
aimed to enhance the range of everyday activities. 
None of the subjects were receiving drugs at the time 
they enrolled in this study. Drug therapy was used 
mainly used for hyperkinesias with methylphenidate 
or for aggressive behavior with haloperidol. Habilita-
tion by sensory integration training was not used at 
our hospital.
knowledge, there is no biological index for the diagno-
sis of PDD.
Our objective was to compare the urinary levels of 
stress （17-OHCS） in PDD subjects with mental retar-
dation （MR, intelligence quotient ［IQ］＜70） （low-
functioning PDD：LFPDD）, PDD subjects without MR 
（IQ≧70）（high-functioning PDD：HFPDD）, and con-
trols. PDDs include autistic disorder, Rett’s disorder, 
childhood disintegrative disorder, Asperger’s disorder 
and PDDs not otherwise specified （PDD-NOSs）. No 
subjects with Rett’s disorder or childhood disintegra-
tive disorder were included in this study.
In this study we also evaluated and compared uri-
nary levels of stress hormone in children with PDDs 
after receiving behavioral or environmental interven-
tion.
?????????????????????
We measured urinary 17-OHCS2） in children with 
PDDs between June 2002 and June 2004. Levels were 
measured in 24 children with LFPDD and 14 with HF-
PDD （Table 1）. The mean age of LFPDD subjects was 
5.4 years （SD＝2.2）, and their mean IQ was 51 （SD＝
14）. The mean age of HFPDD subjects was 6.6 years 
（SD＝2.0）, and their mean IQ was 94 （SD＝12）. We 
used the Tanaka-Binet for less than six years of age 
or WISC-III test for more than six years of age as an 
IQ test.
Levels were measured a second time in 21 of the 24 
LFPDD subjects and 8 of the 14 HFPDD subjects 6 to 
12- months after the first, after the subjects had re-
ceived intervention for developmental disorders；for 
various reasons the remainder did not return to our 
outpatient clinic. The second urinalyses were per-
formed 6 to 12-months after the first ones, after the 
subjects had received behavioral, environmental and/
or drug intervention for their developmental disorders. 
This was not a 24 hour urinary cortisol assessment. 
We used samples of urine accumulated in the bladder 
overnight and collected in the morning. Each urine 
sample was collected from bedtime until rising in the 
morning, and 80 ml was used. Diagnosis of PDD was 
based on the results of interviews, questionnaires, and 
direct observation by DSM- Ⅳ criteria；MR was diag-
nosed by IQ＜704）. As controls, we measured the 
morning urine from 11 typically developed children 
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???　Characteristics of Patients and Controls
Subjects
Age at 
onset
（years）
Sex Diagnosis
IQ 
or 
DQ
Chief complaints
Urinary17-OHCS/creatinine
［mg/g ＊ cre］
Before 
intervention
After 
intervention
LFPDD
 1  4 M Autism 50 Speech delay, hyperactivity 7.35 4.208
 2 11 M PDDNOS, MR, CD 52 Quick to take offense, violence 6.458 5.713
 3  5 M Autism 51 Speech delay, irregular circadian rhythm 13.856 7.766
 4  5 M Autism 63 Communication disorder 12 9.279
 5  7 F Autism 56 Speech delay 12.937 6.804
 6  5 M Autism 65 Playing alone in kindergarten 8.272 6.466
 7  5 M PDDNOS, MR 68 Speech delay, echolaria 4.612 4.826
 8  4 M PDDNOS, MR 53 Communication disorder 13.802 7.714
 9  5 M Autism 53 Speech delay 7.489 7.214
10  5 M Autism 69 Speech delay 7.181 5.018
11  4 M Autism 40 Speech delay 15.5 5.743
12  6 M Autism 45 Speech delay 4.672 5.451
13  6 M PDDNOS, MR 20 Speech delay, insensitiveness, minor anomaly 6.819 5.805
14  3 M Autism 60 Speech delay 9.517 8.561
15  3 F PDDNOS, MR 63 Nystagmus, persistence 10.427 12.342
16 11 F Autism 45 Speech delay 4.881 5.912
17  5 M Autism 45 Speech delay 8.411 11.363
18  3 M PDDNOS, MR 66 Speech delay, poor eye contact 6.11 7.268
19  8 M Autism 62 Speech delay 5.546 4.993
20  5 F Autism 28 Floppy infant 13.109 8.066
21  6 M Autism 29 Speech delay, speaking loudly 6.361 4.838
22  3 F Autism 49 Speech delay, delayed sleep phase 5 ND
23  3 M Autism 35 Speech delay 3.584 ND
24  7 M PDDNOS, MR 65 Communication disorder 7.996 ND
HFPDD
 1  7 M HFPDD 83 Communication disorder 3.868 4.027
 2  8 M Asperger syndrome 91 Hyperactivity 4.889 4.027
 3 10 F HFPDD 100 Attention deficit disorder 5.676 4.529
 4  8 M HFPDD 92 Speech delay 5.135 4.157
 5 10 M HFPDD 78 Communication disorder 5.745 5.506
 6  5 F HFPDD 94 Speech delay, hyperactivity 9.916 6.544
 7  4 M HFPDD 99 Speech delay 9.098 4.906
 8  7 M HFPDD, ODD 76 Speech delay, hyperactivity 6.641 4.702
 9  4 F HFPDD 120 Speech delay 9.214 ND
10  7 M HFPDD 92 Speech delay 5.831 ND
11  4 F HFPDD 79 Hyperactivity 3.688 ND
12  6 M Asperger syndrome 102 Hyperactivity 6.801 ND
13  6 F Asperger syndrome 103 Playing alone 4.688 ND
14  6 M HFPDD 101 Pronounce a word unclearly 6.385 ND
Control
 1  8 M ND 3.519 ND
 2  8 M ND 4.547 ND
 3  8 F ND 5.186 ND
 4 10 M ND 4.786 ND
 5  3 M ND 3.622 ND
 6 10 M ND 4.379 ND
 7  9 F ND 2.692 ND
 8 10 F ND 3.139 ND
 9  6 F ND 5.827 ND
10  6 M ND 5.27 ND
11  8 M ND 3.798 3.523
LFPDD, low functional pervasive developmental disorder；HFPDD, high functional pervasive developmental disorder；M, 
male；F, female；PDDNOS, pervasive developmental disorder not otherwise specified；MR, mental retardation；CD, conduct 
disorder；ODD, oppositional defiant disorder；ND, not done
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Values in the two treatment groups （LFPDD and 
HFPDD） and controls were compared by the Mann-
Whitney non-parametric test, and the values between 
two data collection points in the two treatment groups 
（LFPDD and HFPDD） were compared by the Wilcox-
on non-parametric test. Statistical significance was es-
tablished at the p＜0.05 level. We did not hold an ethi-
cal committee meeting in this study, but we orally 
took an informed consent from all patients’ parents, 
and they agreed to our study.
???????
As a stress indicator, urinary 17-OHCS concentra-
tion in LFPDD at baseline was significantly （p＜
0.0005） higher than in controls （Fig. 1）. Urinary 17-
OHCS concentration in HFPDD at baseline was signifi-
cantly （p＜0.005） greater than in controls （Fig 1）. 
Moreover, urinary 17-OHCS concentration in LFPDD 
was significantly greater than in HFPDD （p＜0.05） 
（Fig. 1）.
After subjects had received intervention for 6 to 12 
months, both LFPDD and HFPDD subjects had signifi-
cantly （p＜0.05） lower levels of 17-OHCS than before 
intervention （Fig. 2, 3）. In LFPDD there was no signif-
icant difference in 17-OHCS level between medicated 
subjects （n＝8） and unmedicated subjects （n＝13）.
Violent or hypersensitive behavior can make it hard 
to take blood samples or saliva samples from patients 
with PDD. Blood samples must be taken in the hospi-
tal, but urine samples can easily be obtained at home. 
Saliva samples were very difficult to take in large 
quantities. We therefore considered that urine samples 
were the best for checking PDD patients for stress. 
We chose morning urine because we considered that 
nocturnally accumulated urine samples would be the 
most stable. In addition, excretion volume of 17-OHCS 
increases in the morning and decreases in the night. 
So we chose morning urine which showed the highest 
level in a day. We examined urinary 17-OHCS and 
creatinine levels simultaneously and calculated the ra-
tios of urinary 17-OHCS to urinary creatinine. The 
units ［mg/g・creatinine］ that we used were very sta-
ble, because the values were divided by those of uri-
nary creatinine. By calculating the ratio of urinary 17-
OHCS to urinary creatinine, we lessened the influence 
of sex or physique. Urinary 17-OHCS was measured 
by an improved method based on the Porter-Silber re-
action2） in which the inter-assay variance was 3.71％ . 
Urinary creatinine was measured with an autoanalyzer 
（JEOL BM 1650 , Tokyo, Japan）. Urinary 17-OHCS 
and creatinine were measured by Sumikin Bio-Science, 
Incorporated （Sagamihara, Japan）.
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one report 5） in which specimens of morning urine 
were used to examine stress in children with atopic 
dermatitis or renal disease. Our objective was to com-
pare the degree of stress in PDD subjects and controls 
by examining urinary 17-OHCS level. There have 
been no reports of urine stress marker examination in 
children with PDDs, and we believe that our study is 
the first report of the importance of examining urinary 
stress markers in children with PDD.
After diagnosis, virtually all of our subjects with LF-
??????????
Selye H1） regarded stress as the rate of wear and 
tear and 17-OHCS as its indicator, and urinary 17-
OHCS/creatinine was higher than in age-related con-
trols in patients with advanced cancer, severe diabetes 
mellitus, myocardial infarction, hypertension and obesi-
ty, alcohol abuse, or psychosocial stress3）. Stress indica-
tors have been studied in adult subjects or parents of 
children with PDD before 6〜9）. However, there is only 
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???.??　Changes of urinary 17-OHCS/creatinine in LFPDDs （n＝21）
Naomitsu Suzuki
PDD and some with HFPDDs had received special as-
sistance at community preschools or primary schools 
with extra staff. Since we explain the details of PDD to 
the patient’s parents and school teachers, it can estab-
lish a good parent-child and teacher-student relation-
ship. We consider that these are the main factors of 
decreasing stress indicator levels in patients with PDD. 
Health examinations of infants in Japan are done at 
less than 1 year of age, and again at 1 year and 6 
months and then at 3 years. There is no subsequent 
health examination before the child enters school at 
age 6 years. Infants who fail to pass the health exami-
nation at age 3 years almost always fail because of 
speech delay, and some of these infants have LFPDD, 
but not HFPDD in our country. LFPDD children tend 
to receive intervention for developmental disorders 
earlier than do HFPDD ones. However, our LFPDD 
subjects showed greater stress than HFPDD subjects. 
Almost all HFPDD children are diagnosed after they 
enter school, so since 2006 we have been performing a 
health examination at age 5 years to pick up these HF-
PDD children early.
Medication does not cure PDD, but some drugs can 
be useful in the management of behavioral problems10）. 
We use methylphenidate for hyperactivity therapy, 
but only in LFPDD patients. We considered that thera-
py with methylphenidate did not influence urinary 17-
OHCS levels, because there was no significant differ-
ence in levels between the medicated and unmedicated 
groups. Therefore, we considered that stress in PDD 
subjects decreased significantly only because of the 
behavioral or environmental intervention, not because 
of the drug treatment. 
We used urine samples in this study, because most 
PDD children show violent and hypersensitive behav-
ior, which can make it very hard to take plasma sam-
ples or saliva samples. Urinary 17-OHCS and blood 
cortisol were a compound related to “wear and tear” 
to stress, and in typically developed children, the 17-
OHCS/creatinine showed no difference by age5）. We 
could not take second urine samples from the compari-
son group, except one sample because of being trans-
ferred to another hospital. Urinary 17-OHCS of one 
control is measured at December 2, 2002, December 7, 
2002 and November 20, 2003. And urinary 17-OHCS/
creatinine level showed 3.578, 3.798 and 3.523, respec-
tively. There is no change of urinary 17-OHCS level in 
one control after one year. It is necessary to accumu-
late more control data in the future.
None of our patients had midline anomalies in the 
brain and the body. We therefore considered that they 
had no monoamine secretion abnormalities due to ab-
normalities of the posterior nuclei of the brainstem. 
Levels of serotonin, a monoamine present in the mid-
line of the brainstem, are influenced by changes in the 
living environment11,12）. Therefore, serotonin in our pa-
tients is not influenced by midline anomaly. We there-
fore advised our patients and their parents to regulate 
the patients’ living environments or rhythms for at 
least 6 months, for example by limiting the time spent 
watching TV to no more than 2 h and regulating the 
circadian rhythms to activate serotonine. In typically 
developed children, urinary 17-OHCS level as a stress 
barometer shows no age-related changes5）. Stress indi-
cator levels in our patients decreased over the 6 
months or more of intervention through the applica-
tion of these measures. It is not known whether activa-
tion of serotonin lessens the urinary concentration of 
stress hormones.
Although we defined MR as IQ＜70, some patients 
with LFPDD who had IQs on the 60 mark increased 
their IQs to over 70 after receiving intervention for 
developmental disorders. For the purposes of this 
study we still defined these patients as having LFPDD.
We concluded that PDD subjects had significantly 
lower urinary levels of stress hormone after receiving 
behavioral or environmental intervention. Most of 
these PDD children—mainly those with LFPDD—and 
their parents are stressed to some degree, and some 
parents or teachers treat them with psychological cru-
elty. These events lead to a vicious circle. Therefore, it 
can be argued that LFPDD children need even more 
urgent intervention for their developmental disorders 
than do HFPDD children.
Early detection and attention are necessary, but few 
pediatricians in Japan can diagnose PDD, because it is 
a difficult condition to diagnose and requires diagnostic 
experience. It is very important for parents or teach-
ers to notice signs of PDD in infancy. Parents need to 
obtain an early consultation with a medical specialist 
in PDD through their local physician. Hopefully this 
will decrease the stress in PDD children and allow 
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them to adapt more readily to school life.
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